China SXT Pharmaceuticals (SXTC) Stock Price, News & Analysis

Company Overview

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Key Stats

• Today's Range: $1.78 to $1.89
• 50-Day Range: $1.20 to $2.43
• 52-Week Range: $0.95 to $11.92
• Volume: 47,822 shs
• Average Volume: 1.20 million shs
• Market Capitalization: $211.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

China SXT Pharmaceuticals Stock Analysis - MarketRank™

China SXT Pharmaceuticals scored higher than 3% of companies evaluated by MarketBeat, and ranked 919th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for China SXT Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

China SXT Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.62% of the float of China SXT Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

China SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in China SXT Pharmaceuticals has recently increased by 79.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

China SXT Pharmaceuticals does not currently pay a dividend.

Dividend Growth

China SXT Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.62% of the float of China SXT Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

China SXT Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in China SXT Pharmaceuticals has recently increased by 79.04%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for China SXT Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for SXTC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, China SXT Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.95% of the stock of China SXT Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 5.02% of the stock of China SXT Pharmaceuticals is held by institutions.

SXTC Stock Analysis - Frequently Asked Questions

How have SXTC shares performed this year?

China SXT Pharmaceuticals' stock was trading at $4.0648 on January 1st, 2025. Since then, SXTC stock has decreased by 55.1% and is now trading at $1.8250.

When did China SXT Pharmaceuticals' stock split?

Shares of China SXT Pharmaceuticals reverse split before market open on Tuesday, February 25th 2025.The 1-8 reverse split was announced on Friday, February 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of China SXT Pharmaceuticals?

Shares of SXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of China SXT Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that China SXT Pharmaceuticals investors own include Marathon Digital (MARA), NIO (NIO), Meta Platforms (META), Alibaba Group (BABA), HEXO (HEXO), JD.com (JD) and Blink Charging (BLNK).

Company Calendar

• Today: 7/06/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SXTC
• CIK: 1723980
• Web: www.sxtchina.com
• Phone: 8652386299087
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.93 million
• Price / Sales: 109.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $243.66 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 116,030,000
• Free Float: 111,445,000
• Market Cap: $211.75 million
• Optionable: Not Optionable
• Beta: 1.18